检验医学 ›› 2017, Vol. 32 ›› Issue (11): 1055-1058.DOI: 10.3969/j.issn.1673-8640.2017.011.026

• 实验室管理_论著 • 上一篇    下一篇

上海地区表皮生长因子受体基因突变检测室间质量评价

蒋玲丽, 肖艳群, 王雪亮, 鲍芸, 杨依绡, 王华梁   

  1. 上海市临床检验中心,上海 200126
  • 收稿日期:2017-01-20 出版日期:2017-11-30 发布日期:2017-12-07
  • 作者简介:null

    作者简介:蒋玲丽,女,1980年生,硕士,副主任技师,主要从事免疫学和分子生物学质量控制工作。

  • 基金资助:
    上海市卫生和计划生育委员会项目 (201640187)

External quality assessment for epidermal growth factor receptor gene mutation determination in Shanghai

JIANG Lingli, XIAO Yanqun, WANG Xueliang, BAO Yun, YANG Yixiao, WANG Hualiang   

  1. Shanghai Center for Clinical Laboratory,Shanghai 200126,China
  • Received:2017-01-20 Online:2017-11-30 Published:2017-12-07

摘要:

目的 分析上海地区临床实验室表皮生长因子受体(EGFR)基因突变检测项目室间质量评价(EQA)的总体情况,对存在问题进行分析,以确保检测质量。方法 2016年2次EQA样本盘各包含5份样本,要求各参评实验室在规定时间内将检测结果上传至上海市临床检验中心数据库。依据回报结果计算各实验室的EQA成绩和样本符合率,并汇总阳性样本和阴性样本的总体符合率。结果 2016年2次EQA分别收到25和30份有效回报结果,分别有20(80%)和26(87%)家实验室检测结果完全正确,分别有0(0%)和1(3%)家实验室EQA成绩<80分;10份样本的符合率最高为100%,最低为88%;阳性样本和阴性样本的总体符合率分别为95.76%和97.27%;复合突变漏检是样本不符合的主要原因,达50%(5/10)。结论 上海地区临床实验室EGFR基因突变检测总体符合率较高,但仍存在问题,复合突变漏检是主要原因;临床实验室应加强质量控制以保证检测结果的准确性。

关键词: 表皮生长因子受体, 基因突变, 室间质量评价

Abstract:

Objective To evaluate the external quality assessment(EQA) performance for epidermal growth factor receptor(EGFR) gene mutation determination in Shanghai,and to discuss and solve the problems in clinical laboratories in order to improve determination quality. Methods EQA program for EGFR determination was set twice a year. Each sample panel of 2016 EQA program contained 5 samples. The participating laboratories were asked to report their results before deadline. The scores of EQA and the overall coincidence rate of each sample were calculated. The overall coincidence rate of positive samples and negative ones were also calculated. Results In 2016,25 and 30 valid laboratory results were received. Totally,20(80%)and 26(87%)laboratories submitted correct results for all samples,and the EQA score of 0(0%) and 1(3%) laboratory was <80. The highest coincidence rate of the samples was 100%,and the lowest rate was 88%. The overall coincidence rates of positive samples and negative ones were 95.76% and 97.27%,respectively. Missed determination in composite mutation samples was a major cause for inconsistency,which was up to 50%(5/10). Conclusions The results of 2016 EQA program suggest that the overall coincidence rate of laboratories enrolled is high,while there exists problems in some laboratories. Missed determination in composite mutation samples is a major cause for inconsistency. Quality control in clinical laboratories is essential to assure accuracy of results.

Key words: Epidermal growth factor receptor, Gene mutation, External quality assessment

中图分类号: